Dtsch Med Wochenschr 2009; 134: S376-S380
DOI: 10.1055/s-0029-1243045
Übersicht | Review article
Pneumologie
© Georg Thieme Verlag KG Stuttgart · New York

Gibt es Vorteile der Fixkombination bei der Therapie von Asthma bronchiale hinsichtlich der Verträglichkeit und Sicherheit?

Are there any advantages of a fixed combination in the treatment of asthma with respect to safety and tolerability?C. Virchow1
  • 1Institut Klinik und Poliklinik für Innere Medizin, Abt. für Pneumologie, Medizinische Fakultät der Universität Rostock
Further Information

Publication History

eingereicht: 16.2.2009

akzeptiert: 23.7.2009

Publication Date:
25 November 2009 (online)

Literatur

  • 1 Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment.  BMJ. 1993;  306 1034-1037
  • 2 Cooper P R, Panettieri Jr R A. Steroids completely reverse albuterol-induced beta(2)-adrenergic receptor tolerance in human small airways.  J Allergy Clin Immunol. 2008;  122 734-740
  • 3 Hasford J, Virchow J C. Excess mortality in patients with asthma on long-acting beta2-agonists.  Eur Respir J. 2006;  28 900-902
  • 4 Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod F B, Bousquet J. Lung function and asthma control with beclomethasone and formoterol in a single inhaler.  Respir Med. 2008;  103 41-49
  • 5 Inman W H, Adelstein A M. Asthma mortality and pressurised aerosols.  Lancet. 1969;  2 693
  • 6 Mcivor R A, Pizzichini E, Turner M O, Hussack P, Hargreave F E, Sears M R. Potential masking effects of salmeterol on airway inflammation in asthma.  Am J Respir Crit Care Med. 1998;  158 924-930
  • 7 Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma.  J Allergy Clin Immunol. 1996;  98 1051-1057
  • 8 Nelson H S, Weiss S T, Bleecker E R, Yancey S W, Dorinsky P M. SMART Study Group . The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol.  Chest. 2006;  129 15-26
  • 9 Papi A, Paggiaro P L, Nicolini G, Vignola A M, Fabbri L M. Inhaled Combination Asthma Treatment versus SYmbicort (ICAT SY) Study Group . Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.  Eur Respir J. 2007;  29 682-689
  • 10 Ratner B. . In: Abramson HA, ed Treatment of Asthma. London; Baillière, Tindall & Cox, Ltd 1952: xiv, 752
  • 11 Salpeter S R, Ormiston T M, Salpeter E E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma.  Ann Intern Med. 2004;  140 802-813
  • 12 Sears M R, Taylor D R, Print C G. et al . Regular inhaled beta-agonist treatment in bronchial asthma.  Lancet. 1990;  336 1391-1396
  • 13 Thongngarm T, Silkoff P E, Kossack W S, Nelson H S. Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma.  J Asthma. 2005;  42 257-263
  • 14 Wolfe J, Laforce C, Friedman B. et al . Formoterol, 24 microg bid, and serious asthma exacerbations: similar rates compared with formoterol, 12 microg bid, with and without extra doses taken on demand, and placebo.  Chest. 2006;  129 27-38

Prof. Dr. Christian Virchow

Klinik und Poliklinik für Innere Medizin, Abteilung für Pneumologie, Medizinische Fakultät der Universität Rostock

Ernst-Heydemann-Straße 6

Phone: 0381/4947-460

Fax: 0381/4947-392

Email: j.c.virchow@med.uni-rostock.de

    >